Still today: Minorities experience longer delays between cancer diagnosis and treatment !

1. Prostate Cancer:
 Among men with prostate cancer, African Americans experience longer treatment delays after being diagnosed than Caucasians. That is the finding of an analysis published early online in Cancer, a peer-reviewed journal of the American Cancer Society. The study suggests that efforts are needed to reduce racial disparities in prostate cancer care in order to provide earlier treatment for African Americans.

African-Americans experience longer delays between diagnosis and treatment of prostate cancer

Date: May 28, 2013, Source: Wiley


2. Breast Cancer:
Breast cancer in women between the ages of 15 and 39 years (adolescents and young adults [AYAs]) constitutes 5% to 6% of all breast cancer cases in the United States. Breast cancer in AYA women has a worse prognosis than in older women. Five-year survival rates are lowest for AYA women, and only a few studies have examined the impact of delay in treatment, race/ethnicity, and other socioeconomic factors on survival in AYA women.

CONCLUSIONS AND RELEVANCE: Young women with breast cancer with a longer TDT have significantly decreased survival time compared with those with a shorter TDT. This adverse impact on survival was more pronounced in African American women, those with public or no insurance, and those with low SES.

JAMA Surg. 2013 Jun;148(6):516-23. doi: 10.1001/jamasurg.2013.1680.

Delay in surgical treatment and survival after breast cancer diagnosis in young women by race/ethnicity.

Smith EC¹, Ziogas A, Anton-Culver H.

3. Effects of Health Insurance and Race on Early Detection of Cancer

Our final study population consisted of the 28 237 Florida residents diagnosed with colorectal cancer, breast cancer, melanoma, or prostate cancer in 1994, for whom information was available on both stage and insurance payer (Table 1⇔). Most patients were older than 65 years of age, and Medicare was the most common type of insurance. Table 2⇔ presents the proportion of patients who were diagnosed at a late stage of cancer for each category of insurance payer and race. The insurance payer was statistically significantly associated with stage at diagnosis for each of the four cancers examined. Patients insured by Medicaid and patients who were uninsured were at greater risk for late stage disease. Non-Hispanic African-Americans were at a greater risk of a late stage diagnosis for breast and prostate cancers. 

Effects of Health Insurance and Race on Early Detection of Cancer

Richard G. Roetzheim,
Naazneen Pal, Colleen Tennant,
Lydia Voti,
John Z. Ayanian,
Annette Schwabe and
Jeffrey P. Krischer
+ Author Affiliations


Affiliations of authors: R. G. Roetzheim, University of South Florida Department of Family Medicine, and Division of Cancer Control, H. Lee Moffitt Cancer Center and Research Institute, Tampa; N. Pal, C. Tennant, University of South Florida Department of Family Medicine; L. Voti, Florida Cancer Data System, Sylvester Comprehensive Cancer Center, University of Miami, FL; J. Z. Ayanian, Division of General Medicine, Department of Medicine, Brigham and Women's Hospital, and Department of Health Care Policy, Harvard Medical School, Boston, MA; A. Schwabe, Department of Chronic Disease Epidemiology, Florida Department of Health, Tallahassee; J. P. Krischer, H. Lee Moffitt Cancer Center and Research Institute.


Correspondence to: Richard G. Roetzheim, M.D., M.S.P.H., University of South Florida Department of Family Medicine, 12901 Bruce B. Downs Blvd., MDC 13, Tampa, FL 33612 (e-mail: rroetzhe@com1.med.usf.edu).

 

A fast-paced life-style induces 'doc-shopping' with unforeseeable consequences...

In the search of perfect health and instant relief from any noticeable sign from the body, some individuals shop and hop from one doctor's office to the other, often without any measurable relief from the perceptions that the body keeps sending - signs of aliveness, wakefulness, tiredness, excitement, fullness after a great meal, shivers from a fright....
A president-like appointment schedule involving 10 or more specialists charts the course of the week, the daily medical trips are punctuated by the ingestion of up to 36 different medications at meticulously recorded times and separated from or taken during meal times as advised...

Over a few innocent weeks and month, unobtrusively, life is turned into a full-time state of disease that demands constant attention, worry, discussion, opposition and scrutiny that ends up creating anxiety not only in the patient, but also in each and every one of his or her family members as they shiver in dark anticipation with every sigh, hiccups, burp and yawn.

The outcry: "Oh well, I don't know what is wrong with me, really!" leads to ever more head scratching... maybe soon these doctors will loose their hair over the puzzling case !
by PK

Help us fund the Testing of Biomarkers to define, monitor and better address OBESITY, A CONDITION OF PROFOUND ENDOCRINE AND CYTOKINE DISTURBANCES, a true state of DISEASE!

Testing  Biomarkers to define, monitor and better address OBESITY,  A CONDITION OF PROFOUND ENDOCRINE AND CYTOKINE DISTURBANCES, a true disease state

We want to establish new guidelines for monitoring obesity by finding specific biomarkers.  Following BMI, lipid profile and pushing diet and physical activity is clearly insufficient.  Blocking the central nervous system to force mental rejection of food is not the answer, either.

Obesity becomes a disease because of its high inflammatory state, determined by a relatively high level of Growth factor and Cytokines inducing major deleterious consequences on the muscle skeletal system through the activated NF-KB. 

In morbid obesity, RIP140 levels are down-regulated in visceral adipose tissue. The RIP 140 (also known as NRIP1) interacts with DAX1 which involves the COPS2,  SREBF1 (the bone modulator) and SF1 ("feminization" of obese individuals). (see literature) In breast cancer, RIP140 is involved in regulation of E2F1, an oncogene which discriminates between luminal and basal tumor types. RIP140 influences cancer phenotype and prognosis.^{. "}In addition, RIP140 has a role in inflammation, since it acts as a coactivator for NFkappaB/RelA-dependent cytokine gene expression. Lack of RIP140 leads to an inhibition of proinflammatory pathways in macrophages and RIP-140 modulation is part of cachexia induced by Tumors. 

Also, in a state of obesity, even outside the cell, there is a relatively large number of insulin molecules."
Without receptors to stimulate, they will go downstream and stimulate MAPK AND STRESS LIKE c-JUN/fos, LEADING TO INCREASED CYTOKINES  with Interferons and interleukins leading to diseases caused by obesity.

HONESTLY

AS WE PROGRESS IN CANCER SCIENCE, THE TIME FOR DIAGNOSIS OF CANCER WITHOUT GENETIC RECIPE AT THE BASIS OF THE DISEASE IS QUITE PASSED!  GIVING OLD CHEMOTHERAPY SHOULD ONLY BE ALLOWED IN REFRACTORY DISEASES...BUT HERE WE ARE, WITH LEADERS DISTRACTED DRIVING US BACKWARDS.... RESARCHERS ARE LEFT FIGHTING OVER WHETHER TO TEST THE DNA, THE RNA OR SIMPLY THE RELATED PROTEIN, AN EXTRA $2000 WOULD HAVE ALLOWED TO PURCHASE THE 50 ELISA KITS, BUT ALL IS FALLING SHORT BECAUSE OF THAT AMOUNT!   IF THIS IS HAPPENING HERE...WHAT ABOUT...? SHOULD WE REALLY BE DISCUSSING THIS NOW?

The Combination of Etoposide and Histone Deacetylases applied to Cancers with high levels of c-MYC and c-FOS gene expression

The Combination of Etoposide and Histone Deacetylases applied to Cancers with high levels of c-MYC and c-FOS gene expression:

This research project investigates the possibility of combining Etoposide with Histone Deacetylases in the treatment of cancers that display a significant expression of te c-Myc and c-Fos gene.  The drugs proposed for this trial are Etoposide and Histone Deacetylases.

Etoposide was first synthesized in 1966 and is a drug widely used in chemotherapy since 1983 when it obtained  FDA approval. Etoposide forms a ternary complex with DNA and the topoisomerase II enzyme which participates in the unwinding of DNA, hence prevents the rwligation of the DNA strands, and by doing so causes DNA strands to break. This action then  leads to DNA synthesis errors and subsequently to cell death. Etoposide has, however, some reported side effects such as low blood pressure, hair loss, pain or burning at the injection site .

Histone deacetylation has been an effective treatment for various types of cancers. By the removal of acetyl groups from histones, histone deacetylases create a non-permissive chromatin conformation that prevents the transcription of genes that regulate the expression of proteins involved in tumor development such as c-FOS. In addition to histones, histone deacetylases deacetylate a variety of other proteins including transcription factors and other abundant cellular proteins involved  in the regulation of cell growth, differentiation and cell death. Histone Deacetylases are among the most promising therapeutic targets for cancer treatment, and they have inspired researchers to study and develop HDAC inhibitors worldwide.

The present research project consists in computerized and laboratory testing of the efficacy of combining these two treatments in cases of observed overexpression of both the c-MYC and c-FOS gene.  Although the two drugs already exist and are used in cancer therapy, the interaction of  the two drugs when used in combination needs to be examined. This can be achieved by using a mouse model bearing specified tumors to be done at the University of Texas at El Paso (UTEP). Preliminary testing should be conducted by implanting cancer cells in the skin of mice. The combined treatment should then be applied indiscriminately to mice presenting high expression of c-Myc and c-FOS, and to those with low expression of these genes. The response to the treatment will be monitored to evaluate the efficacy of the treatment in mice with high c-Myc and c-FOS expression as compared to the control group with low c-Myc and low c-FOS expression. In a later phase, testing would be conducted  in cancer patients presenting high expression of c-Myc and c-FOS, especially for patients treated for triple negative breast cancer, but also for ovarian cancer and other types of cancer with an overexpression of c-MYC.

The combination of Etoposide with Histone Deacetylases represents de facto a novelty in cancer treatment, especially in the case of triple negative breast cancer that is until today associated with a worse prognosis than other breast cancer types. It has a characteristic recurrence pattern with the peak risk of recurrence and the majority of deaths occurring in the first 3 and 5 years after the initial treatment, respectively.

What can we quickly improve through Gene interference! Questions?

*Do various viruses who require intracellular multiplication
also require use of EIF4G?
*Can blocking Cap dependent transcription through the PKC delta an effective antitumor activity during maintenance therapy.
*can we afford anhilation/blocking RAFT1?
*should blocking dimerization of EIF4G an effective therapeutic intervention in Cancer
*Does limitation of activity at the RHEB limit activity of an m-TOR and B-raf inhibitor combination, or RHEB Amplification a sign of resistance or otherwise sensitivity to B-RAF inhibitor, can the RHEB be used as a Bio-marker?
*Activity of RYR1, TRDN genes in Alzheimer dementia
*Does suppression of AGAP2 a sign of hormone failure in ER positive Breast cancer?
*Could blocking SHC exacerbate or Increase Apoptosis and c-MYC amplification

Whims of hope are driving the fight for the cure!

We know we will never win all human competitions which are marred with intrigues,
but because our cause is just,
because the cause is what we believe in,
as a coalition we will continue to fight until the reversal of breast cancer mortality becomes a reality.
and this after the effects of hormone therapy, screening mammogram and improvement in chemotherapy.
We believe in target therapy as an answer to cancer.  And we believe humanity is at a dawn of several break through in cancer treatment.  We believe not to lead from behind but it is not wrong to revisit some known premises that were overlooked!  We believe in the use of new technologies to revisit old premises!  We believe not all aspects were fully visited as the multitude of genes and their interactions did not allow a more comprehensive study that is today's called for.  We believe some will continue to deter the march to the cure because it what they do!  And the escape of the cure needs these agents!  CRBCM will not shrink from its mission, and will continue its progression no matter what,   The cause is too important and too Valuable to let them distract us...we still will summon the rest of our forces to rise to the mission...we will fight until enemies become irrelevant to the train of history, or until the torch to true research is passed on to valiant believers!
It is true the women die of breast cancer every  day, and it is true that cure is achievable, and from these premises lie the true nature of our fight, fight that will call many to answer and many will join.  The CRBCM find its vigor and reason for existence in these premises
and will continue to work with all its might.  Research is an uncharted world, any stone should be turned because where the truth lie is only known to nature and its creator (for those who believe), and many are called to lend a hand in this struggle for the scientific truth that will free those within the scourge of cancer,  The CRBCM stand with them.  They are not alone!  Let this spirit guide our work, until we are convince to have made strides in this war against cancers!

The CRBCM, man enough to show-up!

his is a confirmation e-mail for the following:

Grant-maker: National Cancer Institute - NExT Program
Program: NExT Partnership with NCI (Non-Grants)

Status: Submitted
Status Date: 2/14/2014 10:09:05 PM
Application ID#: 321008
Applicant: Mutombo Kankonde
Institution: Mutombo Kankonde
Title: Etoposide and Histone Deacetylases in Cancers with high c-MYC and c-FOS

To see the updated application status, we recommend that you first logout of proposalCENTRAL and close all proposalCENTRAL browser windows. Then log back in to proposalCENTRAL and access your application from the Manage Proposals tab.

If you need assistance, contact proposalCENTRAL Customer Support at 800 875 2562 (Toll-free U.S. and Canada), +1 703 964 5840 (Direct Dial International) or by e-mail at pcsupport@altum.com.
========================================

New Consults!

Today 3 new consults at CRBCM referred by UMC network!,
1.Pancreatic
2.Renal cell cancer
3.Hepatoma
opening a panoply of genetic abnormality considerations at CRBCM, Good work!
(After a Myeloma, an Embryonal  Sarcoma and 2 Metastatic Colon cancers!)

The Internist's Tumor

No tumor remains of interest as Renal cell cancer, and the interest keeps swelling not only with the incidence of the disease, but with various discoveries in genes and pathways going awry in this disease, scientists working with Target therapy are increasingly embolden to try new staff in kidney disease.  The SWOG trial of Tarceva in papillary Renal cancer is just one demonstration of our confidence in Target therapy.  And believe me it works as predicted!  Overall response of 11% was achieved, and a number of stable diseases yielding an overall control of papillary renal cell cancers in 64 % of patients.   Basically nothing to sneeze at! But this reenforce the notion that papillary cancers (primary c-Met) have a strong VEGF dependency, and that it is here that Tensorilimus may be may work better while Sunitinib will serve better in those diseases where VEGF is a secondary expression such as an secondary amplification as a result of Von Hipple Landau primary activity!

Nonetheless, what really made the name of Internist Tumor to Renal cancers is its associated Cytokine release and no further dedicated and detailed investigation has been fully deployed.  And the main reasons, wright or wrong, have been around the fact that no clear Cytokine adjuvant treatment has made a difference for our patients (to be continued).

Testing the general population for cancer risk!

It is now set!
Our research in cancer predisposition in the general population is shaping up, the consent has been drawn, where to keep the blood well organized, samples will be collected at CRBCM.  they will be stored at the Biomedical science department at UTEP where they will ultimately be analyzed for various Mutations and overexpressions.   up to 300 samples are planned and already candidates are piling up in line.  People are interested in pure research!  We at CRBCM are glad of UTEP's DR Zhang leadership, consent has been devised.  Demographic questionaire is being developed, and cancer survivors are available.
we know cancer follow certain paths, we are going to test these paths on innocent bystanders.
Those genes that will be most expressed may enter a kit.
The testing is on!

NOTES TO EXPAND ON!

Resveratrol, in aging and cardio-protection controversy!
Enzastaurin; inhibitor of Protein Kinase C Beta
Panobinostat
ABT-199---BCL-2 INHIBITOR
DASATINIB SRC-ABL INHIBITOR
FOSTAMATINIB  SYK INHIBITOR
IDELASIB  P13K INHIBITOR
LENALIDOMID IMMUNO-MODULATOR
OBINITUZUMAB ANTI-CD20

BUT WHAT IS
-AVIDIN
-STREPTAVIDIN:  " It is currently thought that this high level of binding to adherent cell types, such as activated platelets and melanomas, is a result of integrin binding mediated through the RYD sequence in streptavidin.[1" WIKIPEDIA.  THIS IS USED IN NANOTECHNOLOGY TODAY.


GENE THAT COUNT DNA DUPPLICATION AND LIMIT IT TO 1, DOES IT PLAY IN VIRAL REPLICATION?

Meeting at UTEP with DR Zhang and DR CHOI

2/11/14
Monthly meeting to mark completion of the first phase of the lung cancer project.  This is preliminary completion of gene detection Mutations that will appear in a Kit for early detection of lung cancer.  Dr Zhang has obtained 77 additional samples that will undergo the same PCR evaluations.
The Inclusion of MUC1 and MUC7 was also discussed.  We are going to test for Avastin resistance through genetic evaluation.
Vista college students were included in the discussion
The insensitivity to stage of disease, and whether or not the patient received treatment was welcome news as the persistence of these genes show strength through time during the neoplastic process and speak to curability particularly if future studies suggest that their persistence point to low disease free progression. 

Today we learned from the tissue bank that surrounding tissue that is normal tissue is available as back ground mutations is needed for comparison/ baseline!

We did not look at genes that may be suppressed in lung cancer such as PTEN.  With PCR, that information is obtainable but tricky whereas amplified or overexpressed gene seem readily obtainable.

Things are still exciting as we progress toward concrete finding.  The MDM2 was the most overexpressed!

is c-fos over expression protective for Colon, Gastric and Bladder cancer? question of the day!

Is c-fos expansion or overexpression protective for Colon, gastric, bladder cancer (we are open to an opposite result)  THIS IS INVESTIGATION AFTER ALL!
Is it why diabetic have less cancer while on Insulin

"Regulation of c-fos expression in adipose and muscle tissue of diabetic rats.

Olson AL, Pessin JE.

Author information

Abstract

Insulin treatment of control rats demonstrated a marked 8-fold transient increase (15 min) in c-fos mRNA in white adipose tissue, which returns to basal levels by 5 h. Similarly, insulin treatment resulted in a rapid 9-fold increase in cardiac muscle c-fos mRNA, "
==========================================

we will look into this and by the way go to article if you need more data!

we believe what is going on with G-proteins and at epigenetic is so preoccupying for the cell that it block key pathway to cancer development....we will further investigate!

more genetic based questions (?future role of Ibrutinib-the wonder drug?)

*Role of Caveolins in stroke and MI. Does this scaffold matter in these disease?  
*what links Psoriasis, breast cancer, androgen, c-MYC, and c-fos, well, well and well, It is the SERUM RESPONSE FACTOR!  LOOK INTO THIS ONE FOR ANSWERS, AND IF YOU LIKE GENE INTERFERENCE THE GTF2I GENE IS YOUR POTENTIAL TARGET.
*IF YOU CONTINUE WITH THIS LOGIC, Ibrutinib is a potential treatment of hormone refractory breast cancer !  eh! why not try it in Myocardial Infarction while at it!
*The use of Anti-phosphodiesterase (caffein, papaverine, theophyline) could maximize or diminish biologic effects of few hormone based anticancer drugs (?Abiraterone).  mostly maximimize it through the PKA?
what effect is larger influx of Calcium has to do at that point.
*Could use of Caffein by impacting Calcium channel worsen Alzheimer?

A little story into genetic investigation leads me to CPRIT and Alfred Gilman.

2 days ago a man I am following  for basic medical problem and follow-up, called my clinic.
One of his daughter who is obese and diabetic was having significant leg pains.  She had developed a cellulitis from an infected wound.  The cellulitis/purulent wound had failed Bactrim and Mupirocin provided by a local Ambulatory clinic.

2 months prior to this incident, the same man had called me for another daughter who is also obese but was found with Breast Cancer Metastatic to the bone.  The lady was on Letrozole.

I knew right away there is a genetic basis for these syndromes given the age of the patients and family congregation.  As a curious mind I tried to think about this in a categorical/objective way.  My current patient who is now in a local Hospital getting Infectious Disease specialist attention had a infected wound.  It is clear that not all diabetics develop such a complication, but those with a Vasculitis do.  So I let my self look up vasculitis...and of course I found that bio-markers of Vasculitis include ANCA, ESR, c-Reactive Protein, leucocytosis and sometime Eosinophilia.

But as I look further, I fell on the Sturge-Weber Syndrome a prominent Vasculitis.   Well, this landed me on the GNAQ gene.  The same gene that is incriminated in the Uveal Melanoma, mind you!
This is a  Guanine nucleotide-binding protein.  The same proteins that gave Alfred Gilman the Nobel Price back in the days.  This same Gilman who was recently embroiled in the CPRIT debacle!  Bless his soul!
 -----------------------------------------------------------------------------------
"G proteins were discovered when Alfred G. Gilman and Martin Rodbell investigated stimulation of cells by adrenaline. They found that, when adrenaline binds to a receptor, the receptor does not stimulate enzymes directly. Instead, the receptor stimulates a G protein, which stimulates an enzyme. An example is adenylate cyclase, which produces the second messenger cyclic AMP.^[4] For this discovery, they won the 1994 Nobel Prize in Physiology or Medicine.^{[5]"  wikipedia}

G proteins are important signal transducing molecules in cells. "Malfunction of GPCR [G Protein-Coupled Receptor] signaling pathways are involved in many diseases, such as diabetes, blindness, allergies, depression, cardiovascular defects, and certain forms of cancer. It is estimated that about 30% of the modern drugs' cellular targets are GPCRs." ^[6]
The human genome encodes roughly 800 ^[7] G protein-coupled receptors, which detect photons (light), hormones, growth factors, drugs, and other endogenous ligands. Approximately 150 of the GPCRs found in the human genome have unknown functions."wikipedia
-----------------------------------------------------------------------------


This man did great work!  I am appreciating even more his work today as I am facing this family where I suspect abnormality of the G proteins must be involved in their ordeal!  But with current standard I can't test this !  Nobody will pay for it!   It could be that Ibrutinb or medication such as this, derivative of Pertusis or cholera toxin could help but with our current knowledge and boundaries, targeting therapy is out of bound!
Or may be minimal dose of Cytoxan and prednisone for God sake!  More clinical trials are needed!

3 important gene findings though

1.As you start ramaging into the genes involved
you soon encounter the PTPN11---PLCG2----BTK (Bruton), but also Lyn, SHC1 to block Apoptosis, and GAB2 that binds Grb2 the begining of trouble ("wild gene").

2.The Breast Cancer inference comes when you bring in C1QBP---PKC zeta---YWHAC which interacts with BCAR1, and you know BRCAs are not far!

3.For 1 of the daughter to be positive for Estrogen Receptor, you must assume that her receptor stays on because of imbalance G protein. (look into the RIC8 which I assume to be decrease! leading to increase of GB gamma  and of course because of the Phosducin -like Protein PHLP1).  Folks I can't test any further, got to wait 10-20 years at the pace of our progress!

Or else call me to help 915-307-3354!
The CRBCM, at work always...

more questions

Tankyrases are definitely the next gene to inhibit
is NME1 the determinant of whether or not a tumor is metastatic, what about NM23-1,2
is the NME1 always expressed in non metastatic tumors?
NME 1 the road to the Aurora?  Is it prognosis or Predictive for the activity of the Aurora and their inhibitors?

Genetic work cogitations

*Should we forget DNA effect, and plunge on epigenic dysruption of etoposide and slowing of processes at the Mitochondria as mechanisms of action of this anti-topoisomerase to define it better?  This may open-up a new way for use of this target therapy.  Now we learn that c-MYC recruitment of Histone acetylase is highly disturbed under this drug!   Acting here, the drug can affect the Histone cover of DNA?

*Is the use of the GLI as intermediate by the Hedgehog circumstantial?  Is it because the Gli is more available?

*Stop the Dicer or Exporting to really be in the Belly of the beast (in liquid cancers?)

*Can work at the C-MYC decrease Cytokine production by disabling this area of the cell?  How this disruption affect the Wnt (and the Notch...  What Ptch1 has to do anyway?

CRBCM is now affiliated with Vista College of El Paso

The CRBCM/Greater East Cancer Center is now affiliated with El Paso Vista College to provide
administrative and clinical ground for training of students.  3 students will start February10, 2014
the practical part of their training.  We at the Cancer Center welcome them, and are ready to provide them with a great opportunity for further development of their skills in our clinical setting.
The CRBCM has provided new computers and relevant equipments that they will need for their training.  We all look forward to their great work at Greater East cancer Center.

What is cancer cure anyway.

It is easy to globally point out cure for cancer patients, if the patient is staying alive after a clear diagnosis of a cancer that is remote in somebody's life.  It is certainly nice to meet someone who "beat" cancer.  "oh 22 years ago, I had my colon removed for cancer".  You cannot imagine what it does to an Oncologist in particular.  This belief that the disease we face daily is "beatable".  We like to believe there is no cancer, or it is under the control of the immune "defense" or defense in general whether immune or not!
As gene goes, abnormality in terminal differentiation or genes that could be mutated and does not involve other interactions, appears to be the one we can cure.  Things, Mutations and abnormal complexes of genes that is localized, peripheral (at the membrane) or in a specific pathway once correctable can lead to cure.
Gleevec will address CML and diseases bearing similar, specific, and a certain KIT Mutation.  Incurrability seem to be brought in by a coexisting abnormality in gene that are "master modulators".  Gens who's functions cannot be clearly limited are tougher to control.
In breast cancer for example, the involvement of Casein Kinase gene is bad since this is a gene phosphorylating diffusely other genes, and the wrong one may be taken in the course,  the direct involvement of gnes placed in the epigenic area seems to suggest a poor outcome. There are gene called "master regulator or master genes" that appear critically irreversible.   EP 300 Mutation appears critically bad.  This is a "wild gene" interacting with all epigenetic events.  Its Mutation persistent after a "cure" means that cure is fundamentally questionable since it cannot be sustained!  These gene Mutation will one day be checked in every one after treatment to establish curability.  At that time, cure will be genetically achievable...EP300 is a strong example of course, it is not alone in this region....(NCOA, MEF,SP1, SIN3A etc...)  as compare to ie POT1 ( Telomere only)....

Keeping the role of MITF, RUNX3 and SIX3 in perspective (keeping notes)

something is definitely cooking here,  just need to put my finger in it!
 
                                              DAPK
                                                   !
                                                   !
                                                  MITF
                                                      !
                                                      !
                                               RUNX3--------TLE---Glycoprotein 130
                                                      !                   !   
                                                      !                   !
                                                      !    SOX3--SIX3-----Wnt     and    SHH Hedge sonic
                                                      !                   !  
                                                      !                  PAX3
                                                      !  
                                                Increase BIM----------Pro-Apoptosis

The value of Water! (scientific speculations)

Every time it comes to mind that we need to explore further the quantity of 2-3 things in our body to prevent stroke and Myocardial infarction.  And really basic things!
1.the quantity of Water in our system!
have we noticed how in a normal body, body without Diabetes or Hypertension or autoimmune disorder and infection, and mostly certain medications, the frequency of strokes and myocardial infraction is unusual....and why is it that people who use less medications may have less of these events?  What this is telling us is either when these diseases are active they actually lead to these events, but potentially, that our current reaction to the existence of these disease is not appropriate and actually precipitate in certain individual and acutely these events?  Does current therapy cause in certain individuals events that are catastrophic in terems of consequences for the patient?
One of the consequence of blood pressure medications is to relatively dehydrate the individual by increasing urination basically.  This fact associated by unnoticed "vasculitis" or vascular adhesiveness (platelet function implied)  may be the start or an irreversible closure of blood vessel in tissue that depend on low volume capillarity!  We are happy that one having lost so much fluid will have low blood pressure when we commit those numbers in the chart, but are we sure the numbers are telling us the patient is really safe being so dehydrated.  Do we know enough about about what are the consequence of such dehydration should a vascular adhesiveness be increased, and what are current bio-markers of such vascular adhesiveness?  In general, we believe that use of Baby Aspirin could compensate our lack of knowledge and Aspirin will keep adhesiveness under-control, then we learned that this is not safe in everybody.   The chronic use of Aspirin will be a chronic stimuli which at cellular genetic level may not be the thing to preconize, we learned this through the kidney response to chronic exposure to Non steroidals.  Intermittent use may be better but which schedule is unknown!


2.  state of "vasculitis"
3.how about the Cytokine?
4.how about cholesterol or Atheroma?

(to be continued)

Activity at CRBCM: Preliminary results seem to concur!

Already the first phase of results from the study funded partially by the CRBCM and MDHonors are completed.  This is a study on lung cancer detection completed on 50 tissues provided by a tissue bank from the University of Virginia.   Preliminary results coming from the University of Texas in El Paso seem to suggest that the genes involved appear consistently in all cancers no matter the stage of disease, types and race of individual bearing the disease.   This fact is strong because it attest to the early occurrence of these mutations in the neoplastic transformation.  It could subsequently point to cure if indeed these mutations are no longer detected since they appear undisturbed no matter the stage of disease.
The test could therefore detect non only the disease early, but cure of the disease, an unprecedented event...But don't let CRBCM jump ahead of its conclusions which have not been finalized until the publication of our first paper.   Big heads will fight these finding as skepticism is stylish , remember the CRBCM is making the research happen, we do not micro-manage the outcomes!  Facts are being fed to us, and they look promising!  Our purpose is to explore, find the facts, and feed them to the community at large, and in the process learn!  learn! and do the deed ......CRBCM, hard at work!

The second phase is to complete the same PCR based tests in matched serum (sera) of individuals who gave the tissues and spin the same tests to confirm the presence of these mutation in the serum.  We intend to show that the mutations are detectable in blood.  Should we demonstrate that the serum can give us the same result, early detection could be demonstrated in blood.   There are caveats however and many have to do with determining that the findings are indeed found in lung cancer.   Detection through PET in positive individual (who carry these mutations without evident mass) is just another hurdle we will have to face.

Corollary detection of specific mutations that makes tumors susceptible  to Avastin will be conducted as part of this series.  One of the curious fact performed by the researcher at UTEP is to use Actin as the reference standard.  A fact that is peculiar and call for questions when we meet next to draft the preliminary draft of the 1st article.  For CRBCM actin could potentially be used as a predictive Biomarker for Taxane and or Platinum effects! or is-it?  We are at the entrance of bigger things we presume!

The CRBCM...advancing deliberately without big brother breathing down our neck.  Science should be free of political pressures! It makes the thruth even more powerful...We are not closed to criticism, just bringing an argument!

What is important with this exercise is learning to do scientific stuff! That is what the people watching did not understand...yes the study has been done in some form, but doing stuff open new doors to a active mind, and a new institution!

TRPM7 (and PLBC)

It is potentially a dangerous gene when mutated (TRPM)
Its autophosphorylation capacity makes it a potential DRIVER gene...
And it is an Ion Channel and therefore has direct implications on cellular depolarisation
Use of Calcium as a co-factor put it center to all function calcium does. It's importance in Traumatic Brain Injury cannot be undermined.  It seemed to be at the center of neuronal death.  It also may impact the NFAT...  
1. Its implication of Alzheimer needs assessment
2. Its role in the endothelium leads to
"Defects in this gene have been associated to magnesium deficiency in human microvascular endothelial cells.<sup>[3]" wikipedia



3.It also has a significant relation with P38 or MAPK and therefore  reaches ATF2, C-MYC,PAX6 and P53
And again through P38, this gene impact the epigenic event commanded by ELK1, ETS1 and MK2 by which it reach the CREB, RAR, and the NFkB/P65.

4.Through the PLBC, it reaches the Inositiol based pathway.
5.  It is unclear if it participates in Micro-vascular disease seen on so many Brain MRI in elderly, raising the issue of whether this will be a biomarker for this silent disease and whether Aspirin is the best course.
6.?Disruption here is accompanied by disturbance of calcium in blood, or dysfunction of Parathyroid?

Focusing on P38!</sup>

Meaning of cancer recurrence

1-Meaning of recurrence
2-disease only slowed down
3-new development of new bypass pathway
4-additional escape mechanism or pathway
5-resistant disease
6-a virus act on a promoter

ie

Transcriptional repression by YY1, a human GLI-Krüippel-related protein, and relief of repression by adenovirus E1A protein

Yang Shi^*,et al.

--------------------------------------------------------------------------------------------------
YY1 and RYB are fair targets for further investigation.
note RYB gene relation with caspase 10!

Then it goes on to destroy the quote: another political game by excluding us! can't make up this stuff !

just a reminder and CRBCM agrees with the following quote:

"The best discoveries in science aren’t predictable,” says HHMI President Robert Tjian. “One of the things that sets HHMI apart from other organizations that support biomedical research is that we free our researchers to follow their scientific instincts—to follow things that pop up unexpectedly.”
HHMI encourages its investigators to push their research fields into new areas of inquiry. By employing scientists as HHMI investigators—rather than awarding them research grants—the Institute is guided by the principle of “people, not projects.” HHMI investigators have the freedom to explore and, if necessary, to change direction in their research. Moreover, they have support to follow their ideas through to fruition—even if that process takes many years.
“The flexibility that comes with HHMI support allows people to move into new scientific areas more easily,” said Erin K. O’Shea, vice president and chief scientific officer. “I can’t emphasize enough how difficult that kind of movement can be with traditional sources of funding.”
Candidates apply directly to HHMI. Applications must be received by June 3, 2014. Successful candidates are expected to meet the following criteria:

• Hold a PhD, and/or MD or equivalent degree.
• Hold a tenured or tenure-track position as Assistant Professor or higher academic rank (or the equivalent) at an eligible U.S. institution. Federal government employees are not eligible.
• Have more than 5 but no more than 15 years of post-training, professional experience.
• Be the principal investigator on one (or more) active, national, peer-reviewed research grants with a duration of at least three years.

Distinguished biomedical researchers will evaluate the applications from the candidates. All semifinalists will be expected to attend a scientific symposium at HHMI in April 2015 and present a brief research talk to HHMI scientific leadership and a final advisory panel. Finalists will be selected shortly after the scientific symposium.
HHMI announced its last open competition in 2012. That competition resulted in the selection of 27 of the nation’s top biomedical scientists as HHMI investigators in 2013. Once selected, HHMI provides each investigator with his or her full salary, benefits, and a research budget over their initial five-year appointment. The Institute will also cover other expenses, including the purchase of critical equipment.
Through the HHMI Investigator Program, the Institute has joined with more than 70 distinguished U.S. universities, hospitals, institutes, and medical schools to create an environment that provides flexible, long-term support for more than 300 Hughes scientists and members of their research teams. HHMI investigators are widely recognized for their creativity and research accomplishments: 172 HHMI investigators are members of the National Academy of Sciences and there are currently 17 Nobel laureates who are HHMI investigators.'"
The Howard Hughes Medical Institute
The Howard Hughes Medical Institute plays an influential role in advancing scientific research and education in the United States. Its scientists, located across the United States, have made important discoveries that advance our fundamental understanding of biology and its relation to human disease. In a complementary program at HHMI's Janelia Farm Research Campus in Loudoun County, Virginia, leading scientists are pursuing long-term, high-risk, high-reward research in a campus designed to bring together researchers from disparate disciplines. The Institute also aims to transform science education into a creative, interdisciplinary endeavor that reflects the excitement of real research. For more information, visit www.hhmi.org.
The Institute’s endowment at the close of fiscal 2013 was about $16.9 billion. HHMI’s headquarters are located in Chevy Chase, Maryland, just outside Washington, D.C.

Related Links

HHMI Investigator Competition Program Announcement (PDF)

List of Eligible Institutions (PDF)

The HHMI Investigator Program

HHMI Selects 27 of the Nation’s Top Biomedical Scientists

For More Information

Jim Keeley

[ 301-215-8858 ]

keeleyj@hhmi.org

Robert Gutnikoff

[ 301-215-8627 ]

gutnikoffr@hhmi.org

NEVER LEAVE YOUR MIND AT PEACE WHEN IT COMES TO GENES (PROGNOSIS OF SENESCENCE)

It is by now quite clear that Senescence is clearly linked to the health of your eyes (given the frequency of cataract in elderly) and intrinsic deterioration of the heart muscle and muscles in general.  Elderly's muscles seem to become hypothrophic without control.  Kidney deterioration seem to follow closely as if an organ shutdown is in the work.  Indeed some genes seems to be at work in a very discrete way indicating to the eyes, the heart, the muscles, and peripherally the kidney that it is time to shut this thing down.   The proof is that keeping exercising seems to fool this message keeping people "young".

At cellular or gene level, the genes that form the muscles must be implicated!  The Myb, MyoD,Myogenein, Myf5, MEF2, GNA12 ...some of which interacts with MDFI (watch out because it is an gene inhibitor):  (look at the leukemias'story when it comes to interacting with inhibitors (our eyes is square and fare in the SIX1))  six1 talks to PAX (Melanoma)    (how this is liked to Breast cancer...well? did you see E2A? It's here though!)

MDFI  (don't say we at CRBCM did not warned you) AND IF YOUR EYES ARE RIVETED ON THIS ONE, DON'T FORGET MDFIC AS A TARGET!  OH! BY THE WAY LOOK-UP ECRG2  (esophageal cancer ) AND RBEL1 WHILE ON THIS! (Why? because it is a rebel gene! think about that!)

"UniProtKB/Swiss-Prot: MDFI_HUMAN, Q99750

Function: Inhibits the transactivation activity of the Myod family of myogenic factors and represses myogenesis. Acts by associating with Myod family members and retaining them in the cytoplasm by masking their nuclear localization signals. Can also interfere with the DNA-binding activity of Myod family members. Plays an important role in trophoblast and chondrogenic differentiation. Regulates the transcriptional activity of TCF7L1/TCF3 by interacting directly with TCF7L1/TCF3 and preventing it from binding DNA. Binds to the axin complex, resulting in an increase in the level of free beta-catenin. Affects axin regulation of the WNT and JNK signaling pathways (By similarity)

ACTIVITIES AT CRBCM AS OF FEBRUARY 2014!

It is critical to our readers to know that CRBCM is still alive, maturing and quickly expanding its reach...
It is mind "troubling" to think where despite our struggles we have position ourselves. It point to one thing, the need for CRBCM and institution such this one is "critically" great.  We are at
1. having chemotherapy patients needing us
2. patients from El Paso depending on us
3.in a week we are presenting at a local Hospital breaking news on gene studies in Breast cancers
4.Last week we were featured in "University of Texas in El Paso (UTEP) news". At least our MDHONORS/CRBCM  financed work on Lung cancer work was featured.
5.We are solicited for presentation and article reviews.
6. Our work on Traumatic Brain Injury (TBI) is selected for potential publication
7.We have presented our work on TBI through the hall of the prestigious UMC (University Medical Center)
And we the reinstitution of CPRIT, we are poised to submit another research proposal (participating is key, our expectation is "zero" for CPRIT is tricky.   We still don't know what this institution is trying to be...
8.We are still "medical Director" at a local Griffols/Talecris Plasma Center. And completed our work there!
9. We have taken over an over 30 year old prominent Medical Practice
10. We still have completed our mission in the snow covered Indianapolis
And yesterday when you were stretching your legs, enjoying a week-end, the CRBCM attended to more than 10 outpatient and inpatient patients who rely on this new clinic for immediate and future care!
11.On February 10, 2 Nursing students will start Rotation at CRBCM,
We will be at NIH, SBIR, and other funding institution submissions,
and most importantly we will continue our blog
 now followed internationally, with more than 35,000 reviews in 1 year!

The CRBCM....the year is still young, we are going to keep moving!